Targeted pill aims to shrink Hard-to-Treat cancers
NCT ID NCT04771520
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug avapritinib in 50 adults with advanced solid tumors that have mutations in the CKIT or PDGFRA genes. The drug blocks enzymes that help cancer cells grow. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also track how long any response lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Avapritinib (a targeted cancer pill)
- What this could lead to
- If successful, avapritinib could offer a new treatment option for people with advanced cancers that have specific genetic mutations, potentially shrinking tumors or slowing their growth.
- What could go wrong
- This is a small, early-phase trial (50 participants) with no control group, so results may not apply broadly. The drug may not work for all tumor types and could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a new blood test spot colorectal cancer return earlier?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields